Drugs / ASP5834
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07094204 | Jul 2025 → Nov 2028 expected | colorectal cancer, non-small cell lung carcinoma, pancreatic ductal adenocarcinoma | Astellas Pharma Inc | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ASP5834 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07094204 ↗ |
| Route | Intravenous | “ASP5834 and panitumumab will be given through a vein.” NCT07094204 ↗ |